World Investment Advisors LLC Takes $1.61 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

World Investment Advisors LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 33,249 shares of the company's stock, valued at approximately $1,614,000. World Investment Advisors LLC owned approximately 0.07% of Amphastar Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of AMPH. GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after purchasing an additional 398 shares during the last quarter. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at $55,000. Blue Trust Inc. raised its stake in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after buying an additional 309 shares in the last quarter. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth $78,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock traded down $2.26 during mid-day trading on Friday, hitting $42.24. 831,517 shares of the company's stock traded hands, compared to its average volume of 401,530. The company has a market cap of $2.03 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. The firm has a 50 day moving average price of $47.14 and a 200 day moving average price of $44.65. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Analysts Set New Price Targets

Several research firms recently weighed in on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price for the company. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $60.33.

Insider Activity

In related news, EVP Yakob Liawatidewi sold 5,214 shares of the company's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company's stock, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the director now owns 31,471 shares of the company's stock, valued at approximately $1,535,784.80. The trade was a 13.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,533 shares of company stock worth $1,676,542. Corporate insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.